
Triomics: AI-driven oncology care, enhancing patient-trial matching & data curation.
Triomics, founded with a mission to revolutionize oncology research and care through intelligent automation, focuses on leveraging AI to assist cancer care providers. The company offers a generative AI-powered platform designed to manage the growing volume of oncology data, reduce cognitive overload for healthcare staff, and streamline operations. Triomics' solutions include enhancing patient-trial matching, curating data for research and precision medicine, and accelerating trial enrollment and quality improvement projects.
Notable affiliated individuals and investors in Triomics include experts in oncology and AI technology, though specific names are not provided. The company has achieved significant milestones in improving the efficiency of oncology care operations and has made a substantial impact by enabling faster trial enrollments and better data management. Triomics' AI-driven approach has positioned it as a key player in transforming cancer care and research, addressing critical challenges faced by healthcare providers.

Biogenesis Trials
mybiogenesis.com

GenomOncology
genomoncology.com

Onc.AI
onc.ai

xCures
xcures.com

Massive Bio
massivebio.com

Nest Genomics
nestgenomics.com

OmicsChart
omicschart.com

Cambridge Cancer Genomics

VieCure
viecure.com

Leal Health
leal.health

Precision Health AI

Known Medicine

ConcertAI
concertai.com

Vysioneer
vysioneer.com

Data Driven Bioscience
Companies similar to Triomics include Biogenesis Trials, GenomOncology, Onc.AI and xCures.
Triomics was founded in 2020.
Triomics' headquarters is located in San Francisco, CA, US.
Triomics' most recent funding round was for $11.3M (USD) in February 2023.
As of Feb 22, 2023, Triomics has raised a total of $14.1M (USD).
Triomics has 50 employees as of Mar 31, 2024.